stockrowBlossomHill Therapeutics, Inc.
BLSMFollow BLSM
Alert me
BlossomHill Therapeutics, Inc. (BLSM) Return on invested capital
BlossomHill Therapeutics, Inc.'s return on invested capital over the twelve months to 30 June 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | — |
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| CRMD CorMedix Inc compare | 38.8% |
| RLMD Relmada Therapeutics, Inc. compare | 0.00% |
| PRTA Prothena Corporation plc compare | 0.00% |
| TECX Tectonic Therapeutic, Inc. compare | 0.00% |
| EDIT Editas Medicine, Inc. compare | 0.00% |
| ASMB Assembly Biosciences, Inc. compare | 0.00% |
| BLSM BlossomHill Therapeutics, Inc. | 0.00% |
| ALT Altimmune, Inc. compare | −34.3% |
| ALLO Allogene Therapeutics, Inc. compare | −108.8% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)